This Royal Society conference brought together stakeholders from industry and academia to explore advances in machine learning and artificial intelligence for biological research, drug discovery and medicine. Whilst these computational technologies are already transforming biological, clinical and pharmaceutical research, significant obstacles remain, in particular around skills, financing, and accessibility. Concerted industry/academia collaboration is required to address these challenges.
Three sessions around biology, chemistry and medicine included talks on machine learning for target discovery and 'omic technologies, AI-based chemoinformatics, and computational clinical trial design, as well as the classical prediction of protein folding, followed by a keynote address from Dr Demis Hassabis CBE FREng FRS (DeepMind).
The conference concluded with a panel discussion that addressed how machine learning and AI can be used to advance medicine and healthcare.
About the conference series
Supported by AstraZeneca, the meeting formed part of the Royal Society’s Transforming our future series in the life sciences. These meetings are unique, high-level events that address the scientific and technical challenges of the next decade. Each conference features cutting-edge science from industry and academia and brings together leading experts from the scientific community, including regulatory, charity and funding bodies.
Watch the event recording